Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

Yiyuan Feng,Caiying He,Chang Liu,Bingjie Shao,Dong Wang,Peijie Wu
DOI: https://doi.org/10.3390/ijms25126444
IF: 5.6
2024-06-12
International Journal of Molecular Sciences
Abstract:Cancer represents a significant threat to human health, and traditional chemotherapy or cytotoxic therapy is no longer the sole or preferred approach for managing malignant tumors. With advanced research into the immunogenicity of tumor cells and the growing elderly population, tumor immunotherapy has emerged as a prominent therapeutic option. Its significance in treating elderly cancer patients is increasingly recognized. In this study, we review the conceptual classifications and benefits of immunotherapy, and discuss recent developments in new drugs and clinical progress in cancer treatment through various immunotherapeutic modalities with different mechanisms. Additionally, we explore the impact of immunosenescence on the effectiveness of cancer immunotherapy and propose innovative and effective strategies to rejuvenate senescent T cells.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the complexity and prospects of tumor immunotherapy in drug development. Specifically, the article focuses on the following aspects: 1. **Concept classification and advantages of tumor immunotherapy**: The paper reviews different concept classifications of immunotherapy and discusses its advantages in cancer treatment, especially its increasingly prominent significance in the treatment of elderly cancer patients. 2. **New drugs and clinical progress**: The article explores the latest achievements in new drug development and clinical progress of immunotherapy methods through different mechanisms in recent years. 3. **The influence of immunosenescence**: The paper studies the influence of immunosenescence on the effect of tumor immunotherapy and proposes innovative and effective strategies to restore the function of senescent T cells. 4. **Immune checkpoint inhibitors (ICIs)**: It introduces in detail ICIs targeting different targets, such as PD - 1, PD - L1, CTLA - 4, etc., as well as the application of these drugs in the treatment of various cancers and the potential of combination therapies. 5. **Adoptive cell therapy (ACT)**: It discusses various forms of ACT, such as CAR - T, CAR - NK, TCR - T and TILs therapies, and their progress and challenges in clinical applications. Overall, this paper aims to comprehensively summarize the latest progress of tumor immunotherapy, explore its potential and challenges in drug development, and provide new ideas and directions for future cancer treatment.